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Gastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide
and there is a constant urge to bring new therapeutics with newmechanism of action into
the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous
change in pathologically imbalanced microRNAs (miRNAs) is capable of transforming
the cancer cell phenotype. This review analyzed preclinical miRNA-based therapy
attempts in animal models of gastric, pancreatic, gallbladder, and colorectal cancer. From
more than 400 original articles, 26 was found to assess the effect of miRNA mimics,
precursors, expression vectors, or inhibitors administered locally or systemically being
an approach with relatively high translational potential. We have focused on mapping
available information on animal model used (animal strain, cell line, xenograft method),
pharmacological aspects (oligonucleotide chemistry, delivery system, posology, route
of administration) and toxicology assessments. We also summarize findings in the field
pharmacokinetics and toxicity of miRNA-based therapy.
Keywords: microRNA, gastric cancer, pancreatic cancer, gallbladder cancer, colorectal cancer, animal model,
mice, preclinical testing
INTRODUCTION
Research in the field of non-coding nucleic acids has advanced extensively in the last 15 years.
It is now well known, that dysregulation of miRNAs, powerful regulators of gene expression, is
associated withmany diseases. MiRNAs are investigated thoroughly in cancer biology and oncology
and the number of published articles is growing (Figure 1). Last 10 years brought us an immense
amount of information about the roles of miRNAs in cancer cell pathophysiology. All described
hallmarks of cancer (Hanahan and Weinberg, 2011) are in relation with some miRNA imbalance
(Ruan et al., 2009). Attempts to therapeutically interfere with miRNAs levels in pathologic cells are
moving forward to preclinical and clinical phases of new therapies development. Although there are
severe limitations and barriers facing miRNA-based therapy, more and more studies are performed
with auspicious results.
The purpose of this review is to analyze preclinical studies carried out on animal models of
selected gastrointestinal cancer (gastric, pancreatic, gallbladder, and colorectal). We have focused
primarily on pharmacological aspects of miRNA-based therapy with the emphasis on delivery
systems, and also on the type of animal model, and on toxicity assessments. Eventually, we
summarize important findings in the field pharmacokinetics and toxicity of miRNA-based therapy
to make the picture comprehensive.
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FIGURE 1 | Number of new publications found by the term “miRNA
AND cancer” in SCOPUS database.
The Biogenesis of Endogenous miRNAs
MiRNAs are endogenous small (∼22 nt) single-stranded
non-coding RNAs. Their main role in the cell lies in
post-transcriptional attenuation of mRNA translation.
The biosynthesis of miRNAs begins in the nucleus. Long
double-stranded transcripts (pri-miRNAs) are formed by
RNA-polymerases II and III. Pri-miRNAs are cleaved by the
ribonuclease Drosha and DGCR8 protein to form pre-miRNAs,
double-stranded chains ∼70 nt long. Pre-miRNAs are then
transported from the nucleus to the cytoplasm via Exportin-5
protein. In the cytoplasm, mature miRNAs are created through
the interaction with endonuclease Dicer and TRBP protein.
Double-stranded formation is rearranged, the guide strand
forms a complex with Argonaut and other proteins forming
miRISC complex, and plays an active role in the gene expression
attenuation. The other strand, called passenger strand, is
usually degraded in the cytoplasm, or persists and may exert
its own biological activity. For detailed information on miRNA
biogenesis see a recent review by Romero-Cordoba et al. (2014).
There are also number of proofs of mature miRNAs’ presence
and activities in the nucleus (Hwang et al., 2007; Park et al.,
2010; Jeffries et al., 2011; Li et al., 2013). It seems that these
miRNAs could transfer from cytoplasm to nucleus and nucleolus
via Exportin-1 and Importin-8 (Li et al., 2013; Wei et al., 2014)
and influence expression of other miRNAs, or of its own (Tang
et al., 2012; Zisoulis et al., 2012; Wei et al., 2014).
Mechanism of Action
MiRNAs bind mainly to the 3′-untranslated region of mRNA
(3′-UTR), although there are several evidences that miRNAs
could bind to the 5′-UTR, or to the coding sequence itself
(Ott et al., 2011; Gu et al., 2014). In the case of imperfect
matching, the duplex mRNA:miRNA is not translated, or
it is translated incompletely and the polypeptide chain is
subsequently degraded. Binding of miRNA to mRNA target also
activates deadenylation of 3′-poly(A) end of mRNA through
deadenylases, which is a first step of mRNA destabilization and
later degradation by 3′- and 5′-exonucleases (Figure 2). Perfect
matching leads to direct cleavage of the target mRNA. Imperfect
matching is more common in animal cells, while perfect
matching is typical for plant cells (Axtell et al., 2011). The binding
specificity is ensured by the seed sequence of miRNA, which
contains 6–8 nt and which is very often conservative through the
species (Hogg andHarries, 2014). OnemiRNA can regulatemany
different genes, and more than 50% of all genes are suggested to
be regulated by miRNAs. Thus, miRNA network affect most of
cellular processes from the basic metabolic maintenance, through
differentiation, cell division and proliferation, to the death (Calin
and Croce, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al.,
2006; Zhang et al., 2013).
In cancer tissues, a lot of changes in miRNA levels could
be found. MiRNAs decreased in cancer cells are termed
tumor suppressors and reversely, oncogenic miRNAs are those
abundant in cancer tissue. There have already been signs
of miRNAs that function both as tumor suppressors, and
oncogenes depending on the cell type and state (context-
dependentmiRNAs) (Esquela-Kerscher and Slack, 2006; Kasinski
and Slack, 2011).
To reverse the pathologic imbalance of miRNAs mature
miRNAs, miRNA-mimics, precursors, or expression vectors
are administered to increase the level of a specific tumor-
suppressor miRNA, and miRNA inhibitors are administered to
decrease the level of oncogenic miRNA (Figure 3). Promising
results of in vitro studies are nowadays being verified on
animal models and first preclinical, or even clinical trials are
under way.
SEARCH STRATEGY
Web of Science database was searched for in vivo studies
published in the last 5 years (2010–2015) that were focused
on colorectal, pancreatic, gallbladder and gastric cancer.
Searching formulasmiRNAAND vivo AND colorectal/pancreatic/
gallbladder/gastric in article topic (title, abstract and keywords)
was used. The search was finished by the end of February 2016.
About 430 articles were found and further analyzed to select the
specific experimental design: at first, induction of a tumor by
transplantation of human or murine tumor cells, or tumor tissue,
then followed by the administration of miRNAmimic, precursor,
expression vector, or inhibitor. The bulk of the studies found by
the searching formula were excluded because of using different
methods, e.g., influencing the expression level of miRNA in
cancer cells before transplantation into the animal body, or
administration of other substances that affect miRNA levels
and processes like natural compounds, siRNAs etc. 26 studies
included in this review matched the aforementioned criteria.
Both the articles themselves and the supplemental materials
were scrutinized with accent on animal model used (animal
strain and gender, xenograft method, cancer cell line, or
source), pharmacological aspects (oligonucleotide chemistry,
delivery system, posology, route of administration), toxicology
assessments (methods and findings), and eventually the
experimental therapy effect. Some of the information could not
be obtained from articles or supplements, as they lacked e.g.,
animal gender specification.
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FIGURE 2 | Biosynthesis and mechanism of action of miRNAs. The biosynthesis begins in the nucleus by transcription of miRNA genes by RNA polymerase II
(Pol II). Long transcripts, pri-miRNAs, are cleaved by Drosha and DGCR8 protein creating pre-miRNA with hairpin structure. Exportin 5 transfers pre-miRNA into the
cytoplasm, where it is processed by Dicer into miRNA duplex. Mature single-strand miRNA forms RISC complex with Argonaut (Ago) and other proteins and
attenuates mRNA translation and leads to the destabilization of mRNA by deadenylation.
OVERVIEW OF THE SELECTED STUDIES
All selected studies assorted by the organ of cancer cells’
origin are summarized in Tables 2–5. Visual summary of
therapeutic strategy, type of animal model and routes of
administration of miRNA-based therapy is demonstrated in
Figures 4–6. We have analyzed 26 studies, 20 of them used
the miRNA replacement therapy regimen, and others were
miRNA inhibitions. Two studies combined miRNA replacement
therapy with chemotherapy, two studies combined miRNA
inhibition with either chemotherapy, or immunotherapy.
Subcutaneous xenograft model was used in 23 cases, orthotopic
xenotransplantation was performed in two experiments,
and combination of both was done in one study. In 17
studies, miRNA-based therapeutics were administered locally,
i.e., injected intratumorally. Five studies involved systemic
administration by tail-vein, or intraperitoneal injection, while
four studies combined both routes of administration in a
separate substudies, or combined systemic administration of
e.g., chemotherapy, with local administration of miRNA-based
therapy.
MiRNAs studied in the selected articles were both known
tumor suppressors, or oncogenes, and also context-dependent
miRNAs whose effect varies according to the type of cancer
cell. All of them influence the main hallmarks of cancer
such as uncontrolled tumor cell proliferation, impaired process
of apoptosis, defects in the control of cell cycle, increased
migration and invasivity, or tumor angiogenesis (Table 1).
Some miRNAs were tested in combination with cytostatic
agents (doxorubicin, gemcitabine, or oxaliplatin) to achieve
sensitization of chemotherapy-resistant cells and tumors, e.g.,
by decreasing the expression of eﬄux proteins such as ABCB1
(P-glycoprotein). The main result of all in vivo studies was
inhibition of tumor xenograft growth, at least in a transient
manner. All results and references could be found in Tables 2–5.
Toxicity assessment was part of 11 studies. It was performed
at least as animal body weight control but usually was followed
by animal behavior observation, histopathology examination of
tissue dissections of various organs (brain, heart, liver, lungs,
spleen, kidney), or blood biochemistry with regard to liver
and kidney functions (blood urea nitrogen, liver enzymes,
bilirubin). There were two declared deaths of experimental
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FIGURE 3 | Strategies in miRNA-based therapy. The most frequently used animal model of cancer is immunodeficient mouse bearing a subcutaneous tumor
created from cells of human origin. In miRNA-based therapy, two concepts are adopted nowadays, which is the replacement therapy (left) and inhibition therapy
(right). Tumor suppressors MiRNAs are decreased in cancer cells and to increase their levels mature miRNAs, miRNA-mimics, precursors, or expression vectors are
administered. Oncogenic miRNAs are abundant in cancer tissue and to silence their effects, various types of miRNA inhibitors could be administered.
animals in the selected studies. These mice were administered
cholesterol-conjugated oligonucleotide, but both were from the
negative control group. The cause of death was not determined
(Ye et al., 2013). One study declared slight but statistically
significant elevation of blood urea nitrogen in the group
of mice treated systemically with mature miRNA conjugated
with carbonate apatite nanoparticles (Hiraki et al., 2015).
Transient hepatotoxicity was found in mice systemically treated
with adenoviral vector Ad-L5-8miR148aT, but the symptoms
were milder than those produced by administration of Ad-
wt (Bofill-De Ros et al., 2015). No immune response to the
RNA-based treatment was reported in the selected studies,
as they used immune deficient strains. Depending on the
specific genotype, nude or severe immunodeficient (SCID) mice
lack normal cytokine production together with other immune
impairments.
The selected studies utilized various types of administered
miRNA-based substances and different delivery systems. These
issues and their fine tuning are the main points in the successful
development of a miRNA-based therapy. Ability to overcome
natural barriers that face transferring an oligonucleotide into
the cell has to be balanced with the extent of toxicity, as
systems with good cell penetration are usually more cytotoxic
in a non-specific manner. To bring a complex sight on
the development of miRNA-based therapy in gastrointestinal
cancer, we gathered relevant information about the type of
substances, delivery systems and routes of administration used
in the selected 26 studies and we discuss them in detail.
The issue of toxicity is described for each delivery system
and later on also for the concept of miRNA-based therapy
itself.
IMPORTANT ISSUES IN THE FIELD OF
miRNA-BASED THERAPY PRECLINICAL
TESTING
Routes of Administration and Delivery
Systems
MiRNA-based therapeutics in animal studies summarized in
this review were administered either systemically, or locally. In
systemic delivery, the intravenous (tail-vein) and intraperitoneal
injections were used (Figure 6). Local administration was
performed as intratumoral injection into the subcutaneous
tumors. Delivery systems employed in the presented studies
include viral vectors, biocompatible cationic polymers and
copolymers, inorganic nanoparticles, atelocollagen, and
liposomes.
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TABLE 1 | Examples of studied miRNAs in association with some of the
hallmarks of cancer and other cancer cells attributes (I, inhibition
strategy; R, replacement strategy).
Cancer cell
attribute
Studied miRNA Replacement or
inhibition
strategy
References
Uncontrolled cell
proliferation
miR-21 I Sicard et al., 2013
miR-27a R Bao et al., 2014
miR-33a R Ibrahim et al., 2011
miR-145 R Ibrahim et al., 2011
miR-218 R He et al., 2012
miR-429 R Sun Y. et al., 2014
Impaired
apoptosis
let-7 I Geng et al., 2011
miR-20a I Chang et al., 2013;
Wang et al., 2013
miR-21 I Frampton et al., 2011;
Sicard et al., 2013
miR-27a R Bao et al., 2014
miR-145 R Ibrahim et al., 2011
miR-4689 R Hiraki et al., 2015
Dysfunction in cell
cycle control
miR-133a R Dong et al., 2013
miR-200a R Cong et al., 2013
miR-218 R He et al., 2012
miR-1266 R Chen et al., 2014
Cell migration and
invasivity
miR-27a R/I Frampton et al., 2011;
Bao et al., 2014
miR-200a R Cong et al., 2013
miR-429 R Sun Y. et al., 2014
miR-1207-5p R Chen et al., 2014
Neoangiogenesis miR-27a I Frampton et al., 2011
miR-27b R Ye et al., 2013
Resistance to
cytostatic agents
miR-103 R Zhang et al., 2015
miR-107 R Zhang et al., 2015
Viral Vectors
Viral vectors could be administered both locally, and systemically
and they include lentiviruses, adenoviruses, and adeno-associated
viruses (Chen et al., 2015). Viral delivery of antisense construct
expression vectors was used to inhibit miR-21 and miR-148a in
animal models of pancreatic cancer (Bao et al., 2014; Bofill-De
Ros et al., 2015), while expression vector for miR-1266/1207-
5p was examined in replacement therapy in gastric carcinoma
(Chen et al., 2014). Viruses are able to effectively deliver miRNA
therapeutics (precursors, mimics, genes, or inhibitors) into the
tumor cell, but their use could be associated with the risk of
insertional mutagenesis, gain of replication competency of viral
particles, or immune activation. Nucleic acid of adenoviruses
(dsDNA viruses) and adeno-associated viruses (ssDNA viruses)
usually do not integrate into the host cell genome, while lentiviral
(ssRNA viruses) integrates (Soriano et al., 2013; Chen et al., 2015).
Adeno-associated viruses are generally less immunogenic, but
adenovirus-based delivery system could produce at least transient
hepatotoxicity (Broderick and Zamore, 2011; Aslam et al., 2012)
as was also observed by Bofill-De Ros et al. in animal model of
pancreatic ductal adenocarcinoma (Bofill-De Ros et al., 2015).
Cationic Polymer Polyethylenimine
In the selected studies, the most frequently used synthetic
polymer was polyethylenimine (PEI). It was utilized to deliver
mimics or expression vectors of miR-34a, miR-206, and miR-
217 in animal model of pancreatic cancer, or miR-33a and
miR-145 in the model of colorectal carcinoma (Tables 4, 5).
PEI is cationic polymer able to produce nanoparticles. It has
linear or branched structure and different molecular weight
according to the reaction conditions during the synthesis. Due
to the positive charge, PEI has high capacity for negatively
charged oligonucleotides and nucleic acids which are moreover
condensed after complexation with PEI, and thus protected
from nucleases. The charge of PEI also facilitate cellular uptake
by electrostatic interaction with negatively charged surface
molecules (e.g., heparin sulfate proteoglycans), after which the
particles enter the cell by endocytosis. PEI is able to disrupt
the endosome and release the cargo into the cytoplasm, which
grants this method high transfection efficacy. The disruption
of endosome is achieved by protonization of PEI and buffering
of acidic environment of the vesicle. These processes are
followed by osmolarity changes and water intake which leads
to the swelling and burst of the endosome (Höbel and Aigner,
2013; Zhang et al., 2013). Better capacity and efficacy is
achieved by branched PEI but at the cost of higher non-
specific cytotoxicity. In the presented studies, mostly linear
PEI is used, like commercially available transfection reagents
ExGen500TM (Euromedex, Mundolsheim, France) and in vivo-
jetPEITM (Polyplus Transfection, Illkirch, France) assigned for
in vivo experiments. Other issues associated with PEI delivery
are an aggregation of created nanoparticles, or opsonization in
the plasma recognized by phagocytes. PEI with high density
of positive charge could also trigger erythrocyte aggregation
and thrombosis (Kanasty et al., 2012). PEI particles could be
conjugated with various molecules [e.g., polyethylene glycol
(PEG), or antibodies] to resolve such difficulties (Malek et al.,
2009). PEI is not a biodegradable polymer, thus its toxicity is
intensively discussed. It depends strongly on molecular weight
and branching (Fischer et al., 1999) and also on the cargo, as it
may neutralize the charge of PEI. There are studies describing
immune activation in vivo, (Beyerle et al., 2011) hepatotoxicity
and lethality inmice (Chollet et al., 2002) and increased apoptosis
in vitro (Merkel et al., 2011), and also those that proved no
immune response, or hepatotoxicity in mice (Bonnet et al., 2008).
Inorganic Nanoparticles—Iron Oxide, and Carbonate
Apatite
Sun et al. used iron oxide nanoparticles to deliver miR-
16 and overcome doxorubicin resistance in animal model
of gastric adenocarcinoma (Sun Z. et al., 2014). Iron oxide
nanoparticles (IONPs) are biocompatible and biodegradable
particles with magnetic properties. They are composed of
magnetite [Fe3O4, iron (II,III) oxide], or maghemite (Fe2O3,
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ferric oxide) and are usually coated with various other molecules
(PEI, PEG, chitosan etc.) to improve their properties (Kievit
and Zhang, 2011). IONPs could also serve as theranostics
(i.e., substances with both diagnostic and therapeutic purpose).
As well as other nanoparticles, IONPs protect nucleic acids
from being cleaved by nucleases (Kievit et al., 2009) but
could also be opsonized in the plasma and recognized by
phagocytes, mainly by the reticuloendothelial system (RES).
Non-coated IONPs are distributed in heart, liver, spleen, lungs,
kidney, brain, stomach, small intestine, and bone marrow,
while the highest concentration are reached in the liver and
spleen due to the elimination by RES and macrophages
(Wang et al., 2010). IONPs enter the cell by endocytosis
and are degraded in the endosomes (Xie et al., 2009).
Particles between 10 and 60 nm are the most effective,
as they undergo limited kidney and liver/RES uptake, and
are absorbed by tumor cells (Kievit and Zhang, 2011).
Cytotoxicity of IONPs coated with PEI occurs in vitro in
higher concentration than is needed for sufficient transfection
(Lellouche et al., 2015). The administration in vivo could
increase blood iron and intracellularly increase oxidative stress
(Mahmoudi et al., 2011). Non-coated particles could produce
hepatotoxicity, and lung or kidney damage (Hanini et al.,
2011).
Study of Hiraki et al. describes utilization of different
inorganic nanomaterial, carbonate apatite nanoparticles. They
used these particles as a delivery system for mature miR-
4689 in animal model of colorectal adenocarcinoma (Hiraki
et al., 2015). Carbonate apatite [Ca10(PO4)6−X(CO3)X(OH)2]
is composed of calcium cations and phosphate and carbonate
anions in defined ratios. It was firstly described as a transfection
reagent and a delivery system for plasmid DNA by Chowdhury
et al. (2006). Nanoparticles of carbonate apatite are stable
in plasma (pH = 7.4), protect nucleic acids from nuclease
cleavage, but in acidic environment of endosomes, they are
quickly degraded. Their cargo is then released and could
probably escape from endosomes, as high effectivity of this
transfection method was proved for DNA (Wu et al., 2015)
and RNA (Hossain et al., 2010). In mice, these nanoparticles
are accumulated in tumor probably due to the EPR effect
(discussed below), but slight accumulation was found also in
the liver (Wu et al., 2015). As this method arose from calcium
phosphate co-precipitation, which is known to produce certain
level of cytotoxicity in vitro, adverse effects in animals were
inquired. In mice, Wu et al. declared no mortality, weight
loss, or histological damage in liver, kidney, and spleen after
administration of common dose, and also after 2.5 and 5-fold
higher doses. They also do not observed any urinary calculi in
a mouse model of repeated administration. The team advanced
to the evaluation of the delivery system on monkeys (macaques
Macaca fascicularis, formerlyM. cynomolgus). Monkeys received
repeated i.v. infusions during a movement restraint. Equivocal
results were obtained, as some animals had reversible increase in
AST, ALT, LDH, and CPK enzymes, but from further analyses of
isoenzymes, authors suggested that these increments might arise
from the stress associated with body restriction rather from heart
or liver damage (Wu et al., 2015).
Atelocollagen
For direct intratumoral treatment, atelocollagen was used in the
study of Frampton et al. in pancreatic ductal adenocarcinoma to
deliver miR-21, miR-23a, and miR-27a (Frampton et al., 2011).
Atelocollagen is a biocompatible and biodegradable polymer. It
was developed and tested in vivo for gene (plasmid) delivery with
controlled release by Ochiya et al. (Ochiya et al., 1999; Hao et al.,
2016). Atelocollagen is prepared from collagen extracted from
bovine dermis. Natural collagen contains specific amino acid
sequences on both C- and N-terminus (“telopeptides”), which are
highly immunogenic. By digestion with pepsin, these telopeptides
are cleaved. The polymer is liquid at low temperatures, but
solidifies at temperatures above 30◦C (Ochiya et al., 2001;
Komatsu et al., 2016). After intramuscular injection of plasmid
DNA in complex with glucose and atelocollagen in mice, the
transfection was efficient and last more than 60 days. No apparent
toxicity, or hematologic changes were observed in this study,
(Ochiya et al., 1999) as well as Frampton et al. described
neither changes in mice body weight, nor serious adverse effects
(Frampton et al., 2011).
Cationic Lipids and Liposomes
For intratumoral administration, several studies used lipid-
based transfection reagent Lipofectamine 2000 (Thermo Fisher
Scientific, Waltham, USA) designed originally for in vitro
experiments, e.g., Dong et al. in animal model of colorectal
adenocarcinoma to deliver miR-133a (Dong et al., 2013).
Pramanik et al. utilized DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate) with co-lipids
formula to deliver plasmid expression vector of miR-34a,
and miR-143/145 cluster systemically in animal model of
pancreatic ductal adenocarcinoma (Pramanik et al., 2011).
Both delivery systems are composed of cationic lipids that
form liposomes, vesicles with lipophilic bilayer and aqueous
core able to encapsulate hydrophilic molecules (Mallick and
Choi, 2014). By electrostatic interaction, cationic lipids have
increased capacity for negatively charged nucleic acids (Xue
et al., 2015). They enter the cells by endocytosis and are able to
destabilize and breach endosomal membrane by interaction with
its phospholipids (Zelphati and Szoka, 1996). Cationic lipids
exert detergent effect on lipid membranes and interact also with
enzymes, thus could irritate cells, decrease proliferation, alter
gene expression, and even trigger cell lysis (Wu et al., 2001). They
share the same advantages and disadvantages that account for
positive charge as cationic polymers. They form aggregates with
plasma proteins leading to RES elimination and accumulation in
spleen and liver (Nchinda et al., 2002; Zhang et al., 2012). With
decrease of positive charge, RNA encapsulation and transfection
efficacy is decreasing. PEGylation increases blood circulation
time of liposomes, (Pathak et al., 2011; Suk et al., 2016) but
could lead to the formation of anti-PEG IgM antibodies (Ishida
et al., 2006). Liposomes are generally less immunogenic than
cationic polymers. But after processing of liposomes, some
RNA molecules might remain on the surface of a particle. In
the studies using siRNA, these residues lead to the significant
immune activation (Xue et al., 2015). Inflammatory response
in the liver followed by hepatotoxicity and with higher doses
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3 even lethality was described (Tan and Huang, 2002; Zhang et al.,
2005).
Pharmacokinetics of Therapeutic
Oligonucleotides
Chemistry, Physico-Chemical Properties, and
Absorption
Pharmacokinetics of therapeutically administered
oligonucleotides is strongly driven by their physico-chemical
properties. Generally, these properties are not sequence-specific
in qualitative point of view, but can be quantitatively different
from sequence to sequence, and could differ also between
chemistries. Native oligonucleotides are small, negatively
charged molecules, which means that the transfer through
lipophilic membranes necessary for the absorption into systemic
blood circulation and also later into the intracellular space is
quite problematic.
The most common change in oligonucleotide chemistry is
the replacement of phosphodiester bond with phosphorothioate
bond in the backbone. This change goes usually hand in
hand with chemical modification of the 2′ functional group
on ribose in the nucleotide (2′-hydroxyl could be substituted
e.g., to 2′-O-methyl, 2′-O-methoxyethyl, or 2′-fluoro group),
and conjugation with cholesterol. These modifications either
increase the stability of oligonucleotides modifying their
susceptibility to RNAse cleavage (phosphorothioate bonds,
2′-O-modifications), or increase cellular uptake of the
molecule (cholesterol conjugation). Cholesterol-conjugated
2′-O-methyl/methoxyethyl-modified oligonucleotides are
sometimes termed “agomiRs” or “antagomiRs” depending on
their mechanism of action, and they were utilized in some
of the studies focused on gastrointestinal cancer presented in
this article (Chang et al., 2013; Wang et al., 2013; Zhang et al.,
2015; Zou et al., 2015). Modification on 2′ position could also
change the affinity of oligonucleotides to plasma proteins which
has a high impact on pharmacokinetics, most importantly on
distribution and excretion (Crooke, 2007).
Another possibility to change oligonucleotide structure is
chemical modification of the ribose forming a 2′,4′-bicyclic
structure, which is termed locked nucleic acid (LNA) (Kumar
et al., 1998). The most common type of LNA is oligonucleotide
with one or more 2′-O-4′-methylene-β-D-ribosyl structure. This
bicyclic bridge locks ribose in one of its conformation increasing
binding affinity and decrease the susceptibility to nuclease
cleavage (Braasch and Corey, 2001).
Various chemical modifications in the oligonucleotide
structure are now available owing to the development of
commercially available miRNA mimics. According to the
information provided by manufacturers, miRNA mimics should
possess higher affinity to miRISC and thus to the mRNA of
interest. MiRNA-mimics should have no off-target biological
activities due to the passenger strand, and should exert higher
effect than native mature miRNAs. The chemistry modifications
differ between passenger and guide strand, and the molecules
could also be triple-stranded (e.g., Exiqon, Vedbaek, Denmark).
Detailed information about the specific chemistry of the
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miRNA mimic are usually not released. Some evidences were
published last year, that bring the commercially available miRNA
mimics into focus because of non-specific dampening effect
on overall gene expression, accumulation of non-endogenous
high molecular weight RNA species and unintentional passenger
strand loading into the RISC discovered after transient
transfection of human cell lines. Søkilde et al. describe variations
even between batches of a commercially available miRNA mimic
obtained from one manufacturer (Søkilde et al., 2015). The
authors emphasize the issue of a proper dosage of miRNA mimic
and its optimization, and suggest to prefer viral and genetic
approaches, as the created transcripts follow the physiological
biosynthesis pathway and their mechanism of action could be
considered as the very same as endogenous miRNAs (Jin et al.,
2015).
Undesirable physico-chemical properties of oligonucleotides
could be attenuated by delivery systems mentioned before, which
subsequently influence pharmacokinetic processes of miRNA-
based therapeutics.
Distribution, Protein Binding, and Tissue
Accumulation
After being absorbed or injected into systemic circulation,
charged molecules of oligonucleotides bind to various plasma
proteins, above all on albumin and α2-macroglobulin (Cheng
et al., 2013). The binding and the distribution is non-
linear, saturable, changes slightly with length and sequence of
oligonucleotides and is different in rodents and in human.
Distribution to the tissues is very quick and prevails over
metabolic degradation (Levin, 1999). Naked oligonucleotides
accumulate in the liver, kidneys, spleen, bone marrow and
lymphatic nodes, while they do not cross the blood-brain barrier,
placental barrier and they are not present in testes.
In the treatment of cancer, accumulation of a drug in the
tumor tissue or in the metastasis site is a desirable state.
MiRNA-based therapeutics could achieve this due to enhanced
permeability and retention (EPR) effect of a tumor. Enhanced
permeability of new vessels and relative lack of lymphatic vessels
in the tumor site was firstly described by Matsumura and Maeda
(1986). Charge-neutral small particles complexed or loaded with
miRNA-based therapeutics have enhanced extravasation and
could accumulate in the tumor. Metastatic sites are generally less
accessible, as their EPR effect is not so significant (Maeda, 2015).
According to the technology of the delivery system used,
miRNA-based therapeutic could accumulate also extratumorally
in various tissues. All cells capable of phagocytosis accumulate
naked oligonucleotides, liposomes, or nanoparticles, e.g., RES
cells present in the liver (Kupfer cells) and in the circulation,
tissue monocytes and macrophages, and proximal tubular cells
(Chen et al., 2015). In this case, the delivery system alone
as a protection could be insufficient, because in plasma, these
particles get coated by proteins recognized by the RES. The
most common defense against RES is PEGylation, binding of
polyethylene glycol substituents on the surface of a nanoparticle
or liposome, which prevent binding of opsonization proteins
and became very common. Contrarily, the excess of PEG on
the surface of a delivery system particle could diminish cellular
uptake, therefore the process of PEGylation should be optimized
(Seto, 2010).
Oligonucleotides, liposomes and polymer-based nanocarriers
enter the cell by active mechanism, endocytosis. Escape from
endosomes is desired to reach the interaction of miRNA with
mRNA, however, this is another obstacle in miRNA-based
therapy. Some of the carriers could enhance endosomal escape
by steric or osmotic effects. pH sensitive molecules could change
structure in relatively acidic environment due to electrostatic
interactions, which is leading to the mechanical disruption of the
vesicle and release of miRNA into cytoplasm (Ju et al., 2014).
Other molecules are accepting H+ (proton sponges) and by
alteration of ion homeostasis cause swelling and burst of the
endosome (Akinc et al., 2005; Chen et al., 2015).
Metabolism of miRNA-Based Therapeutics
Ubiquitous nucleases begin to degrade oligonucleotides shortly
after administration. According to the chemistry changes, free
oligonucleotides are metabolized by 3′- and 5′-exonucleases
or by endonucleases, and the rate of metabolism depends on
the chemical modifications. Endonuclease cleavage is slower
and takes place only when 3′ and 5′ end of oligonucleotide
is protected by methoxyethyl-modified nucleotides. As was
mentioned before, modifications on 2′-hydroxyl on ribose or
structural changes in the backbone such as LNA structure
can decrease the affinity of nucleases to cleave miRNA-
based therapeutics. Also the complexes of oligonucleotides
with nanoparticles or liposomes have modified susceptibility to
nuclease cleavage.
The metabolites of nuclease cleavage are weakly bound to
the plasma proteins and therefore are rapidly excreted in urine.
Oligonucleotides do not undergo liver oxidation by cytochrome
P450, or conjugation processes (Levin, 1999; Crooke, 2007).
Excretion
Oligonucleotides not bound to proteins are excreted in the urine,
while binding to plasma proteins, or other delivery systems
like liposomes and nanoparticles of specific parameters (e.g.,
hydrodynamic diameter up to 5–6 nm) results in protection
from being urinary excreted (Crooke, 2007; Cheng et al., 2013).
As oligonucleotides accumulate also in the liver, they could be
excreted by both these organs. About 10% of the administered
dose of naked oligonucleotides, and 80% of the metabolites are
urinary excreted. The remaining are excreted by faeces, or endure
bound to the tissue, or inside the cells. The elimination half-
life of oligonucleotides is 1–30 days depending on the type of
tissue. This attribute allows designing a therapeutic regimen
comfortable for potential patients with one dose administration
for a week, 2 weeks, or a month (Crooke, 2007).
Toxicity of miRNA-Based Therapy
The toxicity of oligonucleotide administrationwas largely studied
in the field of antisense therapy. In miRNA-based therapy
specifically, toxicity assessments are not a part every in vivo
study and we have very limited information from the first phases
of clinical research. For antisense oligonucleotides not targeted
to miRNAs, there are evidences from rodent and non-rodent
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FIGURE 4 | Pie chart of miRNA therapeutic strategy in the selected
studies.
FIGURE 5 | Pie chart of animal models and xenograft methods in the
selected studies.
animal models, and also from human volunteers. Potential
adverse effects could be provoked by hybridization-dependent
or independent mechanisms, and could be linked with specific
sequence motifs or length of an oligonucleotide. It means that
some of the findings from antisense therapy in general are quite
relevant for extrapolation to miRNA-based therapy.
Immunostimulation was described for phosphorothioate
antisense oligonucleotides. It is a sequence-dependent,
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FIGURE 6 | Pie chart of routes of administration of miRNA-based
therapy in the selected studies.
hybridization-independent process, which leads to the reversible
activation of various immune cells (e.g., NK cells, B lymphocytes,
mononuclear cells) and increased production of cytokines
such as IL-6, IL-12 and interferon γ (Levin, 1999; Henry et al.,
2002). The main responsible sequence motif is CpG (p stands
for phosphodiester bond) or CG palindromic sequences
naturally occurring mostly in bacterial genome (Krieg et al.,
1995). While unmethylated, this motif is recognized by TLR
receptors on immune cells and activates them. The effect is
also exerted by oligonucleotides with both phosphorothioate,
and phosphodiester bonds in the structure. In rodents, which
are more sensitive than primates to this effect, splenomegaly,
lymphoid hyperplasia, and multiple organ mononuclear
infiltrates were described (Levin, 1999).
Another severe adverse effect relating with immunity is an
activation of complement cascade. It prevails over TLR-mediated
immune stimulation in primates and its mechanism is probably
hybridization/sequence-independent originating from physico-
chemical properties (polyanionic character) of oligonucleotides.
In the study of Henry et al., after reaching a threshold
plasma concentration after i.v. infusion, macaques suffered
from emesis, ataxia, and facial edema. Hemodynamic changes
(fluctuation of blood pressure and tachycardia), changes in blood
count (neutropenia followed by neutrophilia), and increase of
cytokines mentioned above were described (Henry et al., 2002).
When maintaining plasma concentration below the threshold,
symptoms were mild or not present, which is in accordance with
the results of phase I clinical study with antisense oligonucleotide
against intercellular adhesion molecule-1 (ICAM-1) (Glover
et al., 1997).
Similar hybridization/sequence-independent mechanism
leads also to the influencing of blood coagulation cascade
observed in rodents, primates and human (Glover et al., 1997;
Henry et al., 1997). Negative charge of oligonucleotides could
inhibit intrinsic tenase complex (consisting of factor IXa and
VIIIa, which activate factor X), and thus leads to the reversible
prolonging of blood clotting and to the increase of activated
partial thromboplastin time (aPTT) (Sheehan and Lan, 1998;
Levin, 1999).
After administration of relatively high doses of antisense
oligonucleotides (above 100 mg/kg in rodents), histological or
laboratory signs of hepatotoxicity and renal toxicity were present
in experimental animals. Mostly, immune-mediated cellular
infiltrations in liver, multi-focal liver necrosis, and proximal
tubules infiltrations were found in rodents. Posology studies
indicate that lower doses (below 3 mg/kg) do not cause liver and
kidney pathologies in monkey and human (Levin, 1999).
Different mechanism could potentially lead to hepatotoxicity,
which was proven in rodents (Grimm et al., 2006). By introducing
oligonucleotides into the cell, enzymes and other proteins that
physiologically deal with these molecules could be saturated,
and thus processing of other endogenous RNAs sharing these
pathways could be diminished (Bader et al., 2010). This effect
was described on mice treated with shRNA (short hairpin
RNA) expression vectors. Mice suffered from multifocal liver
necrosis followed by ascites, edema, increase of bilirubin and
liver enzymes, and decrease of plasma proteins and body weight.
Several mice died within 1 month. There were no signs of
blood count changes, or increases in cytokine productions.
ShRNAs compete of Dicer cleavage and exportin-5 stabilization
in cytoplasm with endogenous pre-miRNAs, therefore mature
liver miRNAs were found decreased and shRNAs precursors
increased in mice with symptoms of hepatotoxicity. As Grimm
et al. studied almost 50 distinct shRNAs, they assume that the
effect was not sequence related (Grimm et al., 2006). Introducing
of miRNA-precursors into the cell could produce the same effect,
but the data concerning safety of miRNA-based therapies are
limited. Again, proper posology studies are needed.
Another possible mechanism of toxicity is hybridization-
dependent. But the toxicity arisen from both binding to the
desired mRNAs, and off-target binding is hypothesized to be rare
(Bader et al., 2010; van Rooij et al., 2012). MiRNA-mimics and
precursors are suggested to be generally better tolerated than
antisense therapy (Bader et al., 2010). One miRNA could regulate
number of genes, frequently functionally linked in a specific
pathway. Targeting more genes in one or more pathologically
deregulated pathway could be beneficial. The potential for
targeting other genes in different pathways still remains, but
influencing of target or off-target genes with impact on cell
viability should be revealed during accurate in vitro testing.
MiRNA-BASED THERAPEUTICS IN
CLINICAL TRIALS
Certain chemical modifications of oligonucleotides structure
and also several delivery systems for miRNAs have already
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entered clinical phase of drug development. There are no reports
of clinical trials of miRNA-based therapies in gastrointestinal
malignancies on which we have focused in this review—
colorectal, pancreatic, gallbladder and gastric cancer. Two
experimental miRNA-based therapies are now listed on
ClinicalTrials.gov. MiR-34a mimics in an amphoteric liposomal
formulation administered i.v. are tested in the phase I in patients
with primary liver cancer and advanced or metastatic lung and
kidney cancer, melanoma, multiple myeloma and lymphoma
(NCT01829971, Adams et al., 2015).
MiR-16 mimic is evaluated in the treatment of malignant
pleural mesothelioma also in the phase I (NCT02369198).
The therapeutic system used is termed TargomiR and it is
based on specific nanoscale delivery system—nonliving bacterial
minicells (EnGeneIC Delivery Vehicle, EnGeneIC, New York,
USA), and targeted to cancer cells by an anti-EGFR antibody,
since EGFR is known to be overexpressed by certain types of
cancer. Kao et al. even published some of the preliminary results
achieved in the cohort of six patients with malignant pleural
mesothelioma describing significant radiologic and metabolic
responses indicated by PET-scan (Kao et al., 2015; Quinn et al.,
2015).
In non-cancer diseases, the first miRNA-based drug in clinical
settings was miravirsen (LNA miR-122 inhibitor) tested as a
hepatitis C treatment. The drug entered clinical trials phase II
(NCT02031133, NCT02508090, NCT02452814), but van den Ree
has recently referred that the development of miravirsen had
been ceased. A more potent miR-122 inhibitor conjugated with
N-acetylgalactosamine entered phase II (RG-101, 2016; van der
Ree et al., 2016).
Other delivery systems, used in the selected animal studies as
carriers for miRNA-based therapeutics, are evaluated in clinical
trials for non-miRNA treatment. Future results from these trials
may serve also for the development of miRNA-based therapies,
as we may obtain e.g., the information about the potential
toxicity, or pharmacokinetic aspects of a specific delivery system
regardless of its cargo.
Lentiviral vectors are mostly used to transfect cells
that are subsequently injected into the patient, e.g., in
the treatment of lymphoma (NCT02337985). Adenoviral
vectors are evaluated in various solid cancers and are usually
administered locally, intraperitoneally, or even intratumorally.
They are tested in urinary bladder cancer (NCT00003167),
ovarian (NCT00964756), breast (NCT01703754), prostate
(NCT01931046), or pancreatic carcinoma (NCT02705196).
Adeno-associated viruses are tested in non-cancer
diseases to deliver genes for the experimental treatment
of hemophilia B (coagulation factor IX; NCT01620801),
lipoprotein lipase deficiency (NCT00891306), Pompe disease
(α-glucosidase; NCT00976352), or genetic retinopathies
(NCT01482195). In gastric cancer, AAV is used to transfect
patient’s dendritic cells, which are later mixed with his T
lymphocytes to produce specific cytotoxic T lymphocytes
injected i.v. back to the patient (NCT02496273). IONPs are
investigated in various applications in biomedicine, above
all in diagnostics and tissue imaging (e.g., NCT00147238,
NCT01895829). Ferumoxyde, superparamagnetic iron
oxide, has already been used in clinical practice in the
United States for the treatment iron-deficiency anemia in
patients with chronic kidney disease. Finally, PEI particles
for delivering gene therapy are utilized in the clinical
trials phase I and II of pancreatic ductal adenocarcinoma
(NCT01274455), hepatocellular carcinoma (NCT00825474)
and urinary bladder carcinoma (NCT00595088, NCT01274455,
NCT00393809).
FUTURE PERSPECTIVES
In addition to animal models and techniques described in
this review, there are also novel and promising approaches to
target miRNAs under development. Very intriguing strategy
present small-molecule inhibitors that target specific miRNAs
(SMIRs, e.g., diazobenzene inhibiting miR-21) that usually
interfere with miRNA biogenesis and maturation (Wen
et al., 2015). SMIRs constitutes a reasonable and evidence
based strategy with strong potential and chance for success.
The progress of screening techniques and computational
stimulation may address bright future in this field. CRISPR/Cas
9 technology is another emerging technique to be used
in miRNA targeting therapy. For instance, construction
of sequence specific CRISPR/Cas9 based miRNA inhibitor
was reported to downregulate miR-17-92 cluster and miR-
21, two canonical oncogenic miRNAs in cancer (Ho et al.,
2015; Narayanan et al., 2016). Since single miRNA has the
potential of regulating thousand genes, long non-coding
RNA (lncRNA) that is capable of binding multiple miRNAs
could consequently impact the expression of thousands of
genes. In light of this potentially fundamental biological
role, all the lncRNAs that act as endogenous miRNA
sponges presents another promising strategy to target
miRNAs in cancer. Finally, it can also be envisioned that
blocking production, transportation and release of exosome
miRNAs may have beneficial effects in controlling cancer
development, and this may be achieved by targeting other
non-cancerous cells such as the inflammatory cells in the cancer
microenvironment.
CONCLUSIONS
MiRNA-based therapies as a new class of targeted therapy
are heading toward from bench to the bedside. It is now
generally accepted and many times proved that influencing
pathologically changed intracellular levels of miRNAs change
oncogenic phenotype of cancer cells in vitro and in vivo.
However, as there is no ideal animal model of a human
pathology, the translational potential of most studies is somehow
limited. In the studies selected for this review, change of
a specific miRNA was followed by significant diminishing
of tumor size or volume in vivo. The subcutaneous tumor
model used in the bulk of the studies clearly do not
respond with microenvironment of the normal tumor cells,
and also the necessary immunodeficiency of experimental
animals do not correspond with immune status of an average
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oncology patient, nevertheless, the results of animal studies are
promising.
Serious obstacles still lie in the way to the clinical practice.
The main issue is efficient delivery of miRNA-mimics,
precursors, expression vectors, or inhibitors. Other important
difficulty is an assessment of a proper dose sufficient for
anticipated intracellular effects, but lacking or possessing
acceptable adverse effects relating to immunostimulation,
blood coagulation, or toxicities that account for the specific
delivery systems. We also see the importance of non-
rodent models in the development of new drugs, as shown
on the immunostimulation triggered by oligonucleotides
which is significantly different in nature in rodents and
primates.
Several miRNAs and delivery system are now tested
in clinical trials. Most of them are in phase I or II.
Together with more information obtained from preclinical
experiments, the results could move us forward on the
way to a new approach in targeted therapy—drugs that
aim on epigenetic mechanisms of pathophysiological
processes.
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